United Therapeutics to Present New Clinical Data on Pulmonary Hypertension and Inhaled Treprostinil at CHEST 2025 Annual Meeting
I'm PortAI, I can summarize articles.
United Therapeutics Corporation will present new clinical data on pulmonary hypertension and inhaled treprostinil at the CHEST 2025 Annual Meeting in Chicago from October 19-22, 2025. The presentations will include interim analysis results from the PHINDER Study and data on inhaled treprostinil's impact on hospitalizations in PH-ILD patients. The company will also sponsor events, including a symposium on PH-ILD management and the Women in Chest Medicine Annual Luncheon.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments